Indonesian President Prabowo Subianto is set to attend the BRICS summit next month in Brazil https://t.co/txrCH8kNyX ...

Eleven former executives of companies linked to Miteni are sentenced to a combined 141 years in prison by an Italian court for one of the largest groundwater contaminations of forever chemicals in Europe https://t.co/EGnHrdwcE8 ...

Core Insights - Equinox Gold Corp. (EQX) has a robust financial position with significant cash flows, supporting its development projects and liquidity [1][6] - The Greenstone mine is a key asset, expected to produce approximately 390,000 ounces of gold annually at full capacity [2][6] - The company plans to pursue deleveraging in the second half of 2025, leveraging strong cash flow generation [1][6] Financial Position - EQX ended Q1 with $173 million in unrestricted cash and $65 million in an undrawn credit facility, indicating strong liquidity [1][6] - B2Gold Corp. (BTG) reported cash and cash equivalents of $330 million and $800 million available for future drawdowns under its credit facility [3] - Eldorado Gold Corporation (EGO) had $978 million in cash and $241 million in available credit, totaling around $1.2 billion in liquidity [4] Production and Growth - The ramp-up at the Greenstone mine is currently underway, targeting an annual production of 390,000 ounces of gold [2][6] - The recent business combination with Calibre Mining Corp. is expected to enhance production growth and cash flow for EQX [2] Valuation and Market Performance - EQX is trading at a forward 12-month earnings multiple of 7.83, which is about 40.5% lower than the industry average of 13.17 [8] - The Zacks Consensus Estimate indicates a year-over-year earnings rise of 135% for 2025 and 123.4% for 2026, although EPS estimates have been trending down recently [9]

MONTCLAIR, N.J., June 27, 2025 (GLOBE NEWSWIRE) -- 180 Degree Capital Corp. (NASDAQ:TURN) (“180 Degree Capital”) today provides notice to its shareholders that the date of the previously announced special meeting of shareholders for the sole purpose of electing directors (“Director Election Special Meeting”) has been moved to September 15, 2025. This change of date resulted from constructive conversations with the shareholders who submitted a demand request on June 17, 2025 (the “Demand Letter”), who acknow ...

Core Insights - Ultragenyx Pharmaceutical Inc. has received Breakthrough Therapy Designation from the FDA for GTX-102 as a treatment for Angelman syndrome [1][2] - The designation highlights the urgent need for effective treatments and the promising clinical results observed with GTX-102 [2] - The Phase 3 Aspire study is currently enrolling participants, with plans for an additional Aurora study to evaluate GTX-102 in other genotypes and ages expected to start later in 2025 [3] Company Overview - Ultragenyx is a biopharmaceutical company focused on developing therapies for serious rare and ultra-rare genetic diseases [7] - The company has a diverse portfolio of approved medicines and treatment candidates aimed at addressing high unmet medical needs [7] - Ultragenyx's management team has extensive experience in the development and commercialization of rare disease therapeutics [8] Product Information - GTX-102 (apazunersen) is an investigational antisense oligonucleotide therapy designed to reactivate expression of the UBE3A gene [4] - The therapy has received multiple designations from the FDA, including Orphan Drug Designation and Fast Track Designation [4] - The Phase 1/2 study demonstrated consistent developmental gains in 74 patients aged 4-17 with a full maternal UBE3A gene deletion [2] Angelman Syndrome Insights - Angelman syndrome is a rare neurogenetic disorder affecting approximately 60,000 people in commercially accessible geographies [5] - The disorder is characterized by cognitive impairment, motor impairment, and seizures, requiring continuous care for affected individuals [6] - There are currently no approved therapies for Angelman syndrome, but animal models suggest potential for symptom improvement at any age [6]

[Music] So I'm here to talk about taming rogue AI agents but essentially want to talk about uh evaluation driven development observability driven but really why we need observability. So, who uses AI? Is that Jim's stupid most stupid question of the day? Probably. Who trusts AI? Right. If you'd like to meet me after, I've got some snake oil you might be interested in buying. Yeah, we do not trust AI in the slightest. Now, different question. Who reads books? That's reading books. If you want some recommenda ...

In a moment of crisis, the world must “reorient the UN away from the preferences of a minority and towards better serving all states”, urge Ban Ki-moon and Helen Clark. The organisation “does not have to be held hostage by a few countries”, they argue https://t.co/nNfxm6Lkq9 ...

中国商务部：伦敦会谈后，中美双方团队保持着密切沟通。近日，经批准，双方进一步确认了框架细节。中方将依法审批符合条件的管制物项出口申请。美方将相应取消对华采取的一系列限制性措施。 ...

India refuses to sign joint statement at the SCO summit https://t.co/3um12fyPY6 ...

Today, the conservative majority on the United States Supreme Court ruled that states can effectively defund Planned Parenthood, the country's largest provider of reproductive health care. In a 63 ruling, the court changed federal law allowing states to unilaterally cut off all Medicaid funding from Planned Parenthood simply on the basis that it provides abortion care. Now, to be clear, abortion makes up only 3%. Abortion care only makes up 3% of Planned Parenthood services.It is a crucial 3% but it's 3%. T ...